Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Patrys Ltd
PABPatrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia. Address: 96-100 Albert Road, Melbourne, VIC, Australia, 3205
Analytics
Objectif de Cours de WallStreet
0.18 AUDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés PAB
Analyse des dividendes PAB
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes PAB
Valorisation des titres PAB
financières PAB
Résultats | 2019 | Dynamique |